Avita Medical, INC 8-K filings

AVITA Medical, Inc. has amended a prior filing to confirm that future advisory votes on executive compensation will be held annually, following stockholder preference.

AVITA Medical reported an 18% year-over-year revenue increase for Q2 2026, raised its full-year revenue guidance, and anticipates achieving cash flow breakeven in Q4 2026.

AVITA Medical has officially appointed interim leader Cary Vance as President and CEO, while naming Jan Stern Reed as Chair of the Board.

AVITA Medical announced its full year 2025 financial results, reporting 11% revenue growth and a significant reduction in net loss, alongside a strategic debt refinancing.

AVITA Medical refinanced its debt with a new $60 million credit facility from Perceptive Advisors and provided an update on its 2025 revenue and 2026 guidance.

AVITA Medical, a leading acute wound care company, announced the appointment of seasoned healthcare executive Joe Woody to its Board of Directors, effective January 1, 2026, alongside the retirement of former Chairman Lou Panaccio.

AVITA Medical reported a 13% decrease in Q3 2025 commercial revenue to $17.1 million, revised its full-year outlook, and amended its credit agreement with OrbiMed.

AVITA Medical announced the departure of CEO James Corbett, appointing Chairman Cary Vance as Interim CEO, and reported preliminary third-quarter revenue of approximately $17 million.

AVITA Medical, Inc. announced a private placement of 17.2 million CHESS Depositary Interests to Australian investors, expecting to raise approximately US$15 million.

AVITA Medical successfully completed a private placement in Australia, raising approximately US$15 million to fund working capital and growth initiatives.

AVITA Medical revises its full-year 2025 revenue guidance and delays profitability targets due to temporary Medicare payment issues, while amending credit terms and highlighting clinical advancements.

AVITA Medical announced the appointment of Dr. Michael Tarnoff to its Board of Directors and the transition of its Board Chair role from Lou Panaccio to Cary Vance.

AVITA Medical, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including an expanded omnibus incentive plan and equity awards for directors and the CEO, despite notable dissent on compensation-related items.

AVITA Medical updates its bylaws to align with recent changes in applicable law regarding stockholder meetings and electronic notices.

AVITA Medical announces a 67% increase in first-quarter revenue and reaffirms its full-year 2025 financial guidance, expecting to generate free cash flow in the second half of the year and achieve GAAP profitability in the fourth quarter.

AVITA Medical enters into a contract manufacturing agreement and amends its distribution agreement with Stedical Scientific to bolster PermeaDerm production and sales.

AVITA Medical amends credit agreement with OrbiMed, adjusts revenue covenants, and reports a 30% increase in Q4 commercial revenue and a 29% increase in full-year revenue.

AVITA Medical has lowered its expected 2024 revenue but anticipates significant growth and profitability in 2025.

AVITA Medical announced a 44% increase in commercial revenue for the third quarter of 2024, reaching $19.5 million, and amended its credit agreement with OrbiMed.

AVITA Medical announced a 29% increase in commercial revenue to $15.1 million for the second quarter of 2024, alongside key regulatory and partnership milestones.

AVITA Medical has secured an exclusive five-year agreement with Regenity Biosciences to market and distribute a collagen-based dermal matrix, pending FDA 510(k) clearance.

AVITA Medical has announced the appointment of Nicole Kelsey as Chief Legal and Compliance Officer, succeeding Donna Shiroma who has retired after six years of service.

AVITA Medical's stockholders elected all nominated directors and approved equity awards for non-executive directors and the CEO at the 2024 Annual Meeting.

AVITA Medical has secured FDA approval for its RECELL GO System, a next-generation autologous cell harvesting device designed to improve wound care management.

AVITA Medical announced a 5.8% increase in commercial revenue for the first quarter of 2024, alongside the launch of a new wound matrix product.

AVITA Medical has lowered its expected first-quarter 2024 revenue due to a slower-than-anticipated conversion rate of new accounts, while reaffirming its full-year revenue guidance at the lower end of the previously provided range.

AVITA Medical announced a 50% increase in fourth-quarter commercial revenue and provided strong revenue growth guidance for 2024, alongside plans for expansion and new product launches.